Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis

BACKGROUND: Targeting CTLA-4 is a recent strategic approach in cancer control: blocking CTLA-4 enhances an antitumor immunity by promoting T-cell activation and cytotoxic T-lymphocyte proliferation. This induction of a tolerance break against the tumor may be responsible for immune-related adverse e...

Descripción completa

Detalles Bibliográficos
Autores principales: Bertrand, Anne, Kostine, Marie, Barnetche, Thomas, Truchetet, Marie-Elise, Schaeverbeke, Thierry
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4559965/
https://www.ncbi.nlm.nih.gov/pubmed/26337719
http://dx.doi.org/10.1186/s12916-015-0455-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4559965/
https://www.ncbi.nlm.nih.gov/pubmed/26337719
http://dx.doi.org/10.1186/s12916-015-0455-8

Ejemplares similares